SCHEMBL880387

SCHEMBL880387

O=C1CC(c2ccsc2)c2ccc3ccccc3c2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 1.00
▸ MAPT P10636 4/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ HTT P42858 2/20 0.58
▸ ALDH1A1 P00352 5/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ MAPK1 P28482 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ POLB P06746 2/20 0.51
▸ IDO1 P14902 2/20 0.49
▸ TP53 P04637 4/20 0.46
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL852442 0.84 LMNA (0.72) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880438 0.80 LMNA (0.74) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880307 0.80 IDO1 (0.70) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL10280365 0.80 LMNA (0.66) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880450 0.80 LMNA (0.66) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880430 0.80 LMNA (0.67) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880388 0.80 LMNA (0.66) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880302 0.79 LMNA (0.65) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880385 0.79 LMNA (0.65) LMNAMAPTSMN1; SMN2HTTALDH1A1
SCHEMBL880297 0.78 LMNA (0.64) LMNAMAPTSMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289022-A1 TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF BRANDEIS UNIVERSITY (US) 2013-10-31 — — US disclosed
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 — — US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 — — EP disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 — — US disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 — — US disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 — — US disclosed
WO-2007089548-A2 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2007-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT LMNA 525/4885MAPT 30/4885SMN1; SMN2 41/4885
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING GOLT1B, NPC1L1, NPC1 LMNA 3569/4885MAPT 640/4885SMN1; SMN2 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback